Drug Trial Radar · NCT05130970
Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Feb 3, 2022
Primary completion
Jan 2, 2024
Study completion Jan 2, 2024
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Nov 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic pulmonary fibrosis (IPF).
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
GaradacimabDrug
Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
PlaceboDrug
Participants received a matching placebo IV loading dose, followed by 3 SC doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs)Time frame: Up to 22 weeks
- Percentage of Participants With TE SAEsTime frame: Up to 22 weeks
- Number of Participants With TE Adverse Events of Special Interests (AESIs)Time frame: Up to 22 weeks
- Percentage of Participants With TE-AESIsTime frame: Up to 22 weeks
- Number of Participants With Garadacimab Induced Anti Drug Antibodies (ADAs) in PlasmaTime frame: At Day 36 and Day 92 after the first treatment
- Percentage of Participants With Garadacimab Induced ADAs in PlasmaTime frame: At Day 36 and Day 92 after the first treatment
- Number of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as Adverse Events (AEs)Time frame: Up to 14 weeks after treatment
- Percentage of Participants With TE Clinically Significant Abnormalities in Laboratory Assessments Reported as AEsTime frame: Up to 14 weeks after treatment
Locations
47 sites in 11 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Pulmonary Associates Clinical Trials AZ
Phoenix, Arizona
National Institute of Clinical Research
Huntington Beach, California
University of Southern California - Center for Advanced Lung Disease
Los Angeles, California
University of California Irvine
Orange, California
Meris Clinical Research
Brandon, Florida
Reliant Medical Research
Miami, Florida
US Associates in Research LLC
Miami, Florida
Lakes Research
Miami Lakes, Florida
Renstar Medical Research
Ocala, Florida
Central Florida Pulmonary Group, PA
Orlando, Florida
University of Kansas Medical Center
Kansas City, Kansas
Jadestone Clinical Research
Silver Spring, Maryland
Hannibal Clinic
Hannibal, Missouri
Weill Cornell Medical Center
New York, New York
Superior Clinical Research
Smithfield, North Carolina
Southeastern Research Center
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Temple University TMS
Philadelphia, Pennsylvania
Clinical Trial Center of Middle Tennesse
Franklin, Tennessee
Elite Medical Research
Dallas, Texas
Southwest Family Medicine Associates
Dallas, Texas
Baylor Scott and White Health - Advanced Lung Disease Specialists
Dallas, Texas
Baylor College of Medicine
Houston, Texas
Royal Adelaide Hospital
Adelaide, Australia
Medizinische Univerität Graz
Graz, Austria
Kepler Universitätsklinikum
Linz, Austria
Universitair Ziekenhuis (UZ) Leuven
Leuven, Belgium
Centre Hospitalier Universitaire Sart Tilman
Liège, Belgium
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Dr. Syed Anees Medicine Professional Corporation
Windsor, Ontario, Canada
Odense Universitetshospital - Lungemedicinsk Forskningsenhed
Odense, Denmark
Fachkrankenhaus Coswig GmbH
Coswig, Germany
Universitaetsklinikum Essen - Ruhrlandklinik (Westdeutsches Lungenzentrum)
Essen, Germany
Medizinische Hochschule Hannover - Klinik für Pneumologie
Hanover, Germany
Petrus Krankenhaus Wuppertal
Wuppertal, Germany
Azienda Ospedaliera Universitaria Ospedali Riuniti Foggia
Foggia, Italy
Centrum Medycyny Oddechowej Bialymstoku
Bialystok, Poland
Twoja Przychodnia Centrum Medyczne Nowa Sol
Nowa Sól, Poland
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.